High levels of IGFBP2 correlate with proliferation, epithelial-to-mesenchymal transition, invasion, and reduction of cell death in glioblastoma, prostate cancer, breast cancer, and melanoma (16, 21–23). This evidence concerns the gene IGFBP2 and prostate carcinoma.